Myasthenia Gravis Patient Network
Official title: Rare Disease Network for Myasthenia Gravis
Funded at George Washington University · NIH-11171992 · Data updated 2026-11-12
This network connects people with myasthenia gravis to researchers to improve diagnosis, find markers in blood and clinical data, and make it easier for patients to join better clinical trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 1, 2019 |
| Project end | August 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $1,454,144 |
| NIH project number | 2U54NS115054-06 |
| Project ID | NIH-11171992 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and children with any form of myasthenia gravis (AChR-positive, MuSK-positive, thymoma-associated, or seronegative) who can enroll at a participating center or provide remote data or samples are ideal candidates.
✕Less likely to help
People without myasthenia gravis or those seeking an immediate new therapy may not receive direct personal benefit because the network focuses on research, monitoring, and trial readiness rather than delivering treatments.
What this research studies
If you have myasthenia gravis, MGNet brings together clinics, researchers, and patients to collect medical records, symptom tracking, and biospecimens over time. The project uses an electronic medical record–linked app for ongoing monitoring and gathers blood and other samples to search for diagnostic and treatment-responsive biomarkers across MG subtypes. Researchers will validate markers that might predict who responds to therapies and refine outcome measures used in trials. The network aims to speed up early-phase clinical trials and improve how doctors measure and treat MG while sharing findings with patients and clinicians.
Why it matters
Potential benefit: If successful, this work could lead to better tests to diagnose MG, markers that predict which treatments will work, and faster, safer clinical trials for patients.
How similar studies have gone: Other rare-disease networks and registries have helped speed trials and identify candidate biomarkers, but many MG biomarkers remain unproven, so this work builds on prior efforts while addressing ongoing gaps.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Kaminski, Henry J — George Washington University
- Study coordinator: Kaminski, Henry J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how autoimmunity causes myasthenia gravis
This project looks at why the immune system attacks the nerve-muscle connection in myasthenia gravis and how different patient groups are affected.
-
Biological age in myasthenia gravis: guiding who responds to treatment
A patient-friendly look at how a person’s biological age, not just their calendar age, might predict how MG patients respond to treatment and how treatments could even reduce biological aging.
-
CapTURE-MG: A patient-friendly MG data toolkit in a common EHR
A multi-site effort to use a streamlined MG toolkit inside the Epic EHR to collect consistent, real-world information about myasthenia gravis from routine care.
-
Rare Disease Network for Myasthenia Gravis
A nationwide effort to improve diagnosis, monitoring, and trial readiness for people with myasthenia gravis through biomarker work and better care tools.
-
Understanding how autoimmune attacks cause myasthenia gravis
Researchers are studying how the immune system mistakenly targets the neuromuscular junction in myasthenia gravis to identify why the disease starts and how it progresses.
-
Mechanistically informed deep learning to study autoreactive B cells in Myasthenia Gravis
A study using advanced computer models to find hidden immune-cell signals in people with Myasthenia Gravis, including those who don’t yet show detectable antibodies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.